Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

359
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

295
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
295
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

399
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
399
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Antihypertensive Care for Tanzanians Living With HIV: Effectiveness Outcomes From the COACH Pilot Trial.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Implementation barriers and facilitators of a virtual telehealth program for patients with persistently poorly controlled type 2 diabetes mellitus: a rapid qualitative analysis approach.

BMC health services research·2026
Same author

Expanding Technology-Enabled, Nurse-Delivered Chronic Disease Care : A Pragmatic, Randomized, Effectiveness-Implementation Trial.

Annals of internal medicine·2026
Same author

Navigating the heat: implementation challenges and opportunities for heat alert communication and rural health data infrastructure.

Frontiers in public health·2026
Same author

Understanding and addressing the health impacts of wildfires on Latines in California.

The journal of climate change and health·2026
Same author

Patient and Clinician Perspectives on Chronic Pain Communication in Advanced Kidney Disease.

Journal of the American Geriatrics Society·2026

Related Experiment Video

Updated: Mar 14, 2026

Touchscreen Sustained Attention Task SAT for Rats
09:31

Touchscreen Sustained Attention Task SAT for Rats

Published on: September 15, 2017

10.4K

Statin Adherence: Does Gender Matter?

Karen M Goldstein1,2, Leah L Zullig3,4, Lori A Bastian5,6

  • 1Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC, 27705, USA. Karen.goldstein@duke.edu.

Current Atherosclerosis Reports
|October 4, 2016
PubMed
Summary

Women face unique challenges with statin adherence, leading to cardiovascular disease (CVD) disparities. Addressing gender-specific factors is crucial for improving statin use and outcomes in women.

Keywords:
GenderMedication adherenceMedication persistenceStatin medications

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Mar 14, 2026

Touchscreen Sustained Attention Task SAT for Rats
09:31

Touchscreen Sustained Attention Task SAT for Rats

Published on: September 15, 2017

10.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Health Disparities

Background:

  • Cardiovascular disease (CVD) remains a leading cause of death in the USA.
  • Statins have reduced cardiovascular mortality, but their benefits are not equally distributed across genders.
  • Women are less likely to use statins and achieve LDL goals compared to men.

Purpose of the Study:

  • To investigate gender-based differences in the provision and adherence to statin therapy.
  • To identify factors contributing to statin adherence disparities between men and women.

Main Methods:

  • Review of existing literature on gender differences in statin use and adherence.
  • Analysis of provider and patient-level factors influencing statin adherence.
  • Exploration of psychosocial and medication intolerance factors.

Main Results:

  • Women exhibit lower adherence rates to statins compared to men.
  • Factors contributing to non-adherence include lower awareness of CVD risk, higher statin intolerance, and caregiving responsibilities.
  • Inadequate gender-specific analyses in clinical trials limit understanding.

Conclusions:

  • Gender-based disparities in statin adherence are influenced by provider, psychosocial, and intolerance factors.
  • Interventions to improve statin adherence must consider women's specific challenges, including age at CVD risk onset and caregiving roles.
  • Addressing these disparities is essential for equitable CVD prevention and treatment outcomes.